Annals of Surgical Oncology : ()
© 2009 Society of Surgical Oncology

Return to article

TABLE 3. Synopsis of results of IA CDDP reported in the literature

Authors	Study	Type of study	No. IA patients	Ages (y)	Sites	Metastases	No. Preoperative CDDP courses	Time of surgery	>90% TN	Survival	EFS
Winkler et al.²⁸ and Fuchs et al.⁵	COSS 1986	Nonrandomized, 2 arms	50	<40	All	Included	2	Week 11	68%	67% at 10 y	63% at 10 y
Ferrari et al.²⁶	IOR-OS 2	Single arm	164	<40	Extremity	Excluded	2	Week 8	NA	72% at 8 y	63% at 8 y
Ferrari et al.²⁶	IOR-OS 3	Randomized, 2 arms	59	<40	Extremity	Excluded	2	Week 8	64%	61% at 8 y	54% at 8 y
Rha et al.²⁷	Korea	Single arm	37	8–41	Extremity	?	3	Week 9	75%	78% at 3 y	55% at 3 y
Bacci et al.²⁵	3-drug study	Randomized, 2 arms	40	<40	Extremity	Included	2	Week 8–9	77%	NA	26% at 5 y
Bacci et al.²⁵	4-drug study	Randomized, 2 arms	72	<40	Extremity	Included	2	Week 10	80%	NA	61% at 5 y
Wilkins et al.	This study	Single arm	47	<21	Extremity	Excluded	3–5 (response dependent)	Wk 10–16 (response dependent)	87%	92% at 10 y	84% at 10 y

IA, intra-arterial; CDDP, cisplatin; TN, tumor necrosis; EFS, event-free survival; NA, not available; COSS, the Cooperative (German-Austrian-Swiss) Osteosarcoma Study; IOR-OS, Istituto Ortopedico Rizzoli.